Ultra18 Supplements LLC – Trademark Portfolio

Entity Type: 16

Ultra18 Supplements LLC holds 1 U.S. trademark filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 35 (Advertising & Business) — 1 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 2 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include ULTRA18. The owner is based in Brooklyn, NY.

1700 Bedford Ave., 9N

Brooklyn, NY 11225

1 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

ULTRA18
ULTRA18
Registered 2021

Trademark Classifications

Ultra18 Supplements LLC's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

35
Advertising & Business (1 filing)

Advertising; business management; business administration; office functions

5
Pharmaceuticals (1 filing)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does Ultra18 Supplements LLC have?

Ultra18 Supplements LLC has 1 U.S. trademark filed with the USPTO. Of these, 1 registered.

What trademark classes does Ultra18 Supplements LLC file in?

Ultra18 Supplements LLC files trademarks across 2 Nice Classification classes. The most active classes are Class 35 (Advertising & Business), Class 5 (Pharmaceuticals). Class 35 covers advertising; business management; business administration; office functions.

What are Ultra18 Supplements LLC's most well-known trademarks?

Ultra18 Supplements LLC's registered trademark portfolio includes well-known marks such as ULTRA18. These are among 1 currently registered trademark in the portfolio.

What is Ultra18 Supplements LLC's trademark registration success rate?

Ultra18 Supplements LLC has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.